Learnings about Aβ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer’s disease immunotherapeutics

Despite ongoing debate, the amyloid β-protein (Aβ) remains the prime therapeutic target for the treatment of Alzheimer’s disease (AD). However, rational drug design has been hampered by a lack of knowledge about neuroactive Aβ. To help address this deficit, we developed live-cell imaging of iPSC-der...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zemin, Jin, Ming, Hong, Wei, Liu, Wen, Reczek, David, Lagomarsino, Valentina N., Hu, Yuan, Weeden, Tim, Frosch, Matthew P., Young-Pearse, Tracy L., Pradier, Laurent, Selkoe, Dennis, Walsh, Dominic M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007750/
https://www.ncbi.nlm.nih.gov/pubmed/36899414
http://dx.doi.org/10.1186/s40478-023-01511-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007750/
https://www.ncbi.nlm.nih.gov/pubmed/36899414
http://dx.doi.org/10.1186/s40478-023-01511-2

Ejemplares similares